Beta Bionics, Inc. Share Price & Technical Analysis
BBNX · $11.82 (+11.40%)
Healthcare / Medical Devices
$11.82
+11.40%
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pat…
Price chart
Seasonality
May has 2 positive and 0 negative years (last 2 years shown)
16% return in May, 55% avg return in past 3 year May month.
-66% return in 2026, 77% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -55% | -8% | -19% | 1% | 16% | – | – | – | – | – | – | – | -66% |
| 25 | 8% | -12% | -42% | -7% | 55% | -15% | 19% | 18% | 7% | 30% | 15% | 2% | 77% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Strong
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$425.12M
P/E ratio
—
52W high
$32.71
52W low
$8.80
Volume
11,28,450
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Beta Bionics, Inc. share price today?
- Beta Bionics, Inc. (BBNX) last traded around $11.82 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BBNX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BBNX. Download the app for real-time alerts.
- How can I analyze Beta Bionics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.